Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor.
| Autor: | Scheinberg M; Hospital Israelita Albert Einstein and Centro de Doenças Autoimunes, Hospital Beneficência Portuguesa, São Paulo, Brazil., Machado LA; Dermatologista Do Centro de Doenças Autoimunes, Hospital Beneficência Portuguesa, São Paulo, Brazil., M Castro LG; Hospital Alemão Oswaldo Cruz - São Paulo, Brazil., Ferreira SB; Clínica Dermatológica Sineida Berbert Ferreira, Maringá, Brazil., Michalany N; Laboratório Paulista de Dermatopatologia, São Paulo, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of translational autoimmunity [J Transl Autoimmun] 2021 Apr 15; Vol. 4, pp. 100099. Date of Electronic Publication: 2021 Apr 15 (Print Publication: 2021). |
| DOI: | 10.1016/j.jtauto.2021.100099 |
| Abstrakt: | Pyoderma gangrenosum manifests as an ulceration of the skin often associated with several systemic diseases. The diagnosis is usually made by exclusion criteria with suggestions made by clinical findings and histological features. It can occur any site but more common in the legs. Advances in translational medicine led to the development of new forms of therapy in chronic inflammatory diseases by the oral administration of Janus kinase inhibitors. We report two cases of chronic ulceration of the skin consistent with the diagnosis of Pyoderma Gangrenosum that went into complete remission after the use of baricitinib. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2021 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|